organization · Reporting owner
Sorrento Therapeutics, Inc.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Celularity Inc
Report date September 29, 2023 · Filed October 05, 2023
Section 16 reporting ended · disclosed 2023-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 5,050,427 |
Ending reported balance
After 2023-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-29 · Sale · Disposed 9,064,539 · Balance 11,357,585 F1: On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., ("Purchaser") entered into that certain Stock Purchase Agreement (the "SPA") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock ("Celularity Common Shares") of Celularity Inc. ("Celularity") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date. F2: Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof. Row 2 · 2023-10-05 · Sale · Disposed 6,307,158 · Balance 5,050,427 F1: On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., ("Purchaser") entered into that certain Stock Purchase Agreement (the "SPA") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock ("Celularity Common Shares") of Celularity Inc. ("Celularity") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date. F2: Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., ("Purchaser") entered into that certain Stock Purchase Agreement (the "SPA") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock ("Celularity Common Shares") of Celularity Inc. ("Celularity") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date.
F2: Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof.
Scilex Holding Co
Report date September 21, 2023 · Filed September 25, 2023
Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,917,210 |
Reported balance
After 2023-09-21 transaction · row 1
1 source rowRow 1 · 2023-09-21 · Sale · Disposed 60,068,585 · Balance 1,917,210 F1: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-11-10 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-21 · Sale · Disposed 4,490,617 · Balance 0 F1: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2023 Filed Oct 5, 2023 17:16 UTC | Celularity Inc CELU · Entity 7145 | SaleClass A Common Stock | 6,307,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-107259 · tm2327884-1_4seq1.xml · nonDerivative · entry 2 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,050,427 F1 · price: On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., ("Purchaser") entered into that certain Stock Purchase Agreement (the "SPA") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock ("Celularity Common Shares") of Celularity Inc. ("Celularity") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date. F2 · price: Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof. Read SEC document |
| September 29, 2023 Filed Oct 5, 2023 17:16 UTC | Celularity Inc CELU · Entity 7145 | SaleClass A Common Stock | 9,064,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-107259 · tm2327884-1_4seq1.xml · nonDerivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,357,585 F1 · price: On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., ("Purchaser") entered into that certain Stock Purchase Agreement (the "SPA") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock ("Celularity Common Shares") of Celularity Inc. ("Celularity") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date. F2 · price: Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 16:27 UTC | Scilex Holding Co SCLX · Entity 7345 | SaleWarrants to Purchase Common Stock · Derivative | 4,490,617 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-23-103527 · tm2326753-1_4.xml · derivative · entry 2 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,490,617 shares Expires 2027-11-10 F1 · price: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 16:27 UTC | Scilex Holding Co SCLX · Entity 7345 | SaleCommon Stock | 60,068,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-103527 · tm2326753-1_4.xml · nonDerivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,917,210 F1 · price: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 16:11 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherCommon Stock | 73,740,795 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002368 · doc4.xml · nonDerivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,985,795 F1 · kind: On January 19, 2023, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 75,999,853 shares of common stock of Scilex Holding Company held by the Reporting Person (the "Dividend Shares") to record holders of the Reporting Person's common stock and certain warrants to purchase the Reporting Person's common stock as of January 9, 2023 (the "Record Date"). An aggregate of 2,259,058 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of certain holders of warrants to purchase shares of common stock of the Reporting Person who may be entitled to such shares pursuant to the terms of the applicable warrants following the exercise of such warrants, and at the time such shares are distributed to the applicable warrantholders, the Reporting Person will file a Form 4 reporting such distribution. F2 · kind: (Continued form footnote 1) The Reporting Person distributed 0.1410127 of a share of the Issuer's common stock for each share of the Reporting Person's common stock outstanding as of the close of business on the Record Date. The stock ratio was calculated by dividing 76,000,000 by the number of shares of the Reporting Person's common stock and warrants to purchase shares of the Reporting Person's common stock outstanding on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of the Reporting Person who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares. F1 · shares: On January 19, 2023, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 75,999,853 shares of common stock of Scilex Holding Company held by the Reporting Person (the "Dividend Shares") to record holders of the Reporting Person's common stock and certain warrants to purchase the Reporting Person's common stock as of January 9, 2023 (the "Record Date"). An aggregate of 2,259,058 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of certain holders of warrants to purchase shares of common stock of the Reporting Person who may be entitled to such shares pursuant to the terms of the applicable warrants following the exercise of such warrants, and at the time such shares are distributed to the applicable warrantholders, the Reporting Person will file a Form 4 reporting such distribution. F2 · shares: (Continued form footnote 1) The Reporting Person distributed 0.1410127 of a share of the Issuer's common stock for each share of the Reporting Person's common stock outstanding as of the close of business on the Record Date. The stock ratio was calculated by dividing 76,000,000 by the number of shares of the Reporting Person's common stock and warrants to purchase shares of the Reporting Person's common stock outstanding on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of the Reporting Person who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 19:21 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseWarrants to Purchase Common Stock · Derivative | 224,841 | $0.35 Strike: $11.50 | $78,851.74 |
DisclosureSEC source: 0000899243-22-037521 · doc4.xml · derivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,490,617 Underlying: Common Stock · 224,841 shares Expires 2027-11-10 F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.32 to $0.36 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price. Read SEC document |
| November 25, 2022 Filed Nov 25, 2022 15:21 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseWarrants to Purchase Common Stock · Derivative | 46,172 | $0.44 Strike: $11.50 | $20,195.63 |
DisclosureSEC source: 0000899243-22-037015 · doc4.xml · derivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265,776 Underlying: Common Stock · 46,172 shares Expires 2027-11-10 F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.37 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 17:59 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseWarrants to Purchase Common Stock · Derivative | 442,829 | $0.40 Strike: $11.50 | $175,670.26 |
DisclosureSEC source: 0000899243-22-036956 · doc4.xml · derivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,219,604 Underlying: Common Stock · 442,829 shares Expires 2027-11-10 F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2444 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price. Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 19:24 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseWarrants to Purchase Common Stock · Derivative | 672,775 | $0.23 Strike: $11.50 | $152,047.15 |
DisclosureSEC source: 0000899243-22-036807 · doc4.xml · derivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,776,775 Underlying: Common Stock · 672,775 shares Expires 2027-11-10 F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.13 to $0.28 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:38 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherWarrant to Purchase Common Stock · Derivative | 307,296 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0000899243-22-035922 · doc4.xml · derivative · entry 2 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,104,000 Underlying: Common Stock · 307,296 shares Expires 2027-11-10 F2 · kind: Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI (Plan) Ltd ("Sponsor Two" and together with Sponsor One, the "Sponsors") pursuant the Warrant Transfer Agreement (as described below). F3 · price: Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the "Warrant Transfer Agreement"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I ("Vickers") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the "Proxy Statement/Prospectus") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company ("Scilex") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:38 UTC | Scilex Holding Co SCLX · Entity 7345 | OtherWarrant to Purchase Common Stock · Derivative | 2,796,704 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0000899243-22-035922 · doc4.xml · derivative · entry 1 Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,796,704 Underlying: Common Stock · 2,796,704 shares Expires 2027-11-10 F1 · kind: Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI Pte Ltd ("Sponsor One") pursuant the Warrant Transfer Agreement (as described below). F3 · price: Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the "Warrant Transfer Agreement"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I ("Vickers") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the "Proxy Statement/Prospectus") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company ("Scilex") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.